GBA1 and Parkinson disease: Specific histone deacetylase or Hsp90 inhibitors acting as pharmacological chaperones such as ambroxol or isofagomine may therefore be beneficial, and clinical trials are in progress.6, 8 In terms of personalized medicine, a strategy of combined chaperone and GCase augmentation‐based “cocktail” therapy could be useful for GBA‐positive carriers who remain at risk of conversion to clinical PD.